SK bioscience Invests $3M in U.S. Biotech Fina Biosolutions

Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience

September 17, 2024

Pharmaceuticals

Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.

Asahi Kasei Medical Acquires Bionova Scientific

April 14, 2022

Biotechnology

Asahi Kasei Medical agreed to wholly acquire Bionova Scientific, a Fremont, California-based biopharmaceutical CDMO that provides process development and GMP-compliant manufacturing services for next-generation antibody drugs. The acquisition, executed through a U.S. subsidiary, expands Asahi Kasei Medical's bioprocess and CDMO capabilities to better serve biologics developers and accelerate growth of its bioprocess business; closing is subject to regulatory clearances.

BYG4lab to Acquire Finbiosoft with Support from Keensight Capital

March 14, 2024

Software

BYG4lab has signed an exclusivity agreement to acquire Finbiosoft, a Finland-based provider of quality and laboratory software for medical laboratories, with the support of Keensight Capital. The deal is intended to broaden BYG4lab's product capabilities, add Finbiosoft's technical team, and expand the group's geographic footprint across Europe and into the United States while enabling cross-selling to an expanded client base.

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Biotechnology

Sanofi will acquire clinical-stage biopharmaceutical company Vicebio in a deal worth up to $1.6 billion, including $1.15 billion upfront and $450 million in milestone payments. Vicebio, created by Medicxi using the University of Queensland's Molecular Clamp technology, develops multivalent vaccines targeting respiratory viruses and recently advanced a bivalent RSV/hMPV candidate into Phase 1 trials.

Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN

February 1, 2024

Biotechnology

Biovian and 3P Biopharmaceuticals have combined under their common shareholder Keensight Capital to form 3PBIOVIAN, a pan‑European biologics CDMO offering end‑to‑end development and manufacturing across microbial and mammalian protein expression, viral vectors, cell therapy and plasmid DNA. The combined group will operate sites in Pamplona‑Noáin (Spain) and Turku (Finland), maintain a commercial office in Boston, and employ over 500 professionals with gross sales above €75m; ERES IV (advised by Elyan Partners) and Sodena will remain minority shareholders alongside Keensight.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.